ProShare Advisors’s Xenon Pharmaceuticals XENE Stock Holding History

ProShare Advisors’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$967K	Sell	16,020 -230	-1%	-$12.8K	﹤0.01%	815
2026 Q1	$945K	Sell	16,250 -1,029	-6%	-$47.4K	﹤0.01%	807
2025 Q4	$774K	Buy	17,279 +1,539	+10%	+$64.6K	﹤0.01%	912
2025 Q3	$632K	Sell	15,740 -2,708	-15%	-$95.4K	﹤0.01%	991
2025 Q2	$577K	Buy	+18,448	New	+$602K	﹤0.01%	1049
2024 Q2	–	Sell	-5,286	Closed	-$228K	–	2020
2024 Q1	$228K	Buy	5,286 +565	+12%	+$26K	﹤0.01%	1604
2023 Q4	$217K	Buy	+4,721	New	+$167K	﹤0.01%	1592
2023 Q1	–	Sell	-5,172	Closed	-$204K	–	1921
2022 Q4	$204K	Buy	+5,172	New	+$188K	﹤0.01%	1489
2022 Q1	–	Sell	-7,266	Closed	-$227K	–	2309
2021 Q4	$227K	Buy	+7,266	New	+$217K	﹤0.01%	1955

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ProShare Advisors's XENE Position: Q2 2026 in Review

ProShare Advisors reduced its Xenon Pharmaceuticals (XENE) stake by 1.4% in Q2 2026, selling an estimated $12.8K and leaving 16,020 shares worth $967K. The position accounts for ﹤0.01% of the portfolio, ranked #815.

ProShare Advisors first reported a position in XENE in Q4 2021 and has held it in 9 quarters since. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

ProShare Advisors held 16,020 shares of Xenon Pharmaceuticals worth $967K as of Q2 2026.
ProShare Advisors sold 230 Xenon Pharmaceuticals shares in Q2 2026, an estimated $12.8K.
Xenon Pharmaceuticals made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #815 holding.
ProShare Advisors first reported a position in Xenon Pharmaceuticals in Q4 2021 and has held it in 9 quarters since.
315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.